Manufacturer
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG
Contents
Per 25/5 mg FC tab Empagliflozin 25 mg, linagliptin 5 mg
Indication
Adjunct to diet & exercise to improve glycemic control in adults w/ type 2 DM when treatment w/ both empagliflozin &/or linagliptin ± metformin do not provide adequate glycaemic control.
Instruction
May be taken with or without food: Swallow whole w/ water.
Drug interaction
Increased risk of hypoglycaemia w/ insulin & sulphonylureas. Empagliflozin: Increased risk of dehydration & hypotension w/ thiazide & loop diuretics. Decreased efficacy by uridine 5'-diphosphoglucuronosyltransferases (UGT) inducers. Linagliptin: Reduced efficacy w/ strong P-glycoprotein or CYP450 inducers.
Malaysia
